Table 1.
Clinical and pathological features of the enrolled patients
| Variables | Prostate cancer (All, n = 994) | Prostate cancer (TMA, n = 210) |
|---|---|---|
| Age (years) | 67.1 ± 7.1 | 65.7 ± 10.6 |
| BMI | 24.24 ± 3.05 | 24.34 ± 2.75 |
| Preoperation PSA (ng/mL) | 24.90 ± 53.5 (n = 963) | 40.38 ± 102.96 (n = 208) |
| Preoperation f/tPSA (ng/mL) | 0.12 ± 0.08 (n = 613) | 0.11 ± 0.09 (n = 140) |
| pT category (AJCC 2002) | ||
| pT2 | 663 (66.7%) | 121 (57.6%) |
| pT3 | 275 (27.6%) | 82 (39.0%) |
| PT4 | 24 (2.4%) | 7 (3.4%) |
| NA | 32 (3.2%) | |
| Gleason grade | ||
| ≤3 + 3 | 180 (18.1%) | 11 (5.2%) |
| 3 + 4 | 331 (33.3%) | 66 (31.4%) |
| 4 + 3 | 171 (17.2%) | 37 (17.6%) |
| ≥4 + 4 | 262 (26.4%) | 96 (45.8%) |
| NA | 50 (5%) | |
| pN category | ||
| pN0 | 724 (72.9%) | 130 (61.9%) |
| pN+ | 58 (5.8%) | 43 (20.5%) |
| NA | 212 (21.3%) | 37 (17.6%) |
| Prostate capsule invasion | ||
| Negative | 726 (73.0%) | 128 (61.0%) |
| Positive | 250 (25.2%) | 82 (39.0%) |
| NA | 18 (1.8%) | |
| Seminal vesicle invasion | ||
| Negative | 820 (82.5%) | 157 (74.8%) |
| Positive | 155 (15.6%) | 53 (25.2%) |
| NA | 19 (1.9%) | |
| Surgical margin | ||
| Negative | 631 (63.5%) | 114 (54.3%) |
| Positive | 344 (34.6%) | 96 (45.7%) |
| NA | 19 (1.9%) | |
| Nerve invasion | ||
| Negative | 653 (65.7%) | 113 (53.8%) |
| Positive | 322 (32.4%) | 97 (46.2%) |
| NA | 19 (1.9%) | |
| Follow‐up time (Days) | 1295.1 ± 631.6 | 681.2 ± 617.5 |
| Number of biochemical recurrence | 346 | 128 |
| Number of death | 36 | 8 |
TMA, tissue microarray; BMI, body mass index; PSA, prostate specific antigen; NA, not available.